Treg resistance of MS T cells in humanized mice is IL-6-dependent, as the single administration of the IL-6R blocking mAb Tocilizumab restored Treg-mediated suppression, mitigated course of systemic inflammation and ensured survival of the mice. Here, IL6R is linked to myeloid sarcoma.